Whitehawk Therapeutics, Inc.
WHWK Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$3.33
KIRA · Stoqly’s AI analyst, in plain words
- Whitehawk Therapeutics, Inc. had $7.1M of revenue in fiscal 2025, down 72.5% on the year before. Over five years, revenue changed −12.6% a year on average.
- Its operating margin was −1,601.1%, down 1,341.5 pts: of every 100 in sales, about −1,601 is left after running the business.
- Whitehawk Therapeutics, Inc. lost $20.6M in fiscal 2025.
- Free cash flow was −$98.0M in fiscal 2025, −1,371.4% of revenue.
Market cap
$276M
P/E
—
Revenue
$7.1M
Net income
−$20.6M
Free cash flow
−$98.0M
Operating margin
−1,601.1%
Whitehawk Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−72.5%
No. Sales fell 72.5% last year.
Does it make a profit?
−288.3%
No. It lost money last year.
Does profit turn into cash?
−1,371.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Whitehawk Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Whitehawk Therapeutics, Inc.
- CIK
- 0001422142
Whitehawk Therapeutics, Inc. · WHWK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $14.0M | $15.2M | $24.4M | $26.0M | $7.1M |
| Revenue growth | 0.0% | 8.7% | 60.1% | 6.7% | −72.5% |
| Gross margin | 100.0% | 91.2% | 88.5% | 88.4% | 89.4% |
| Operating margin | −794.4% | −411.9% | −295.4% | −259.6% | −1,601.1% |
| Net income | −$110M | −$60.5M | −$65.8M | −$63.7M | −$20.6M |
| Net margin | −786.4% | −397.7% | −270.0% | −245.1% | −288.3% |
| Diluted EPS | −$12.41 | −$2.69 | −$2.44 | −$2.36 | −$0.33 |
| Cash | |||||
| Cash from operations | −$22.4M | −$49.6M | −$59.7M | −$59.6M | −$97.4M |
| Capital expenditure | $0.0M | $0.4M | $4.0M | $1.7M | $0.6M |
| Free cash flow | −$22.5M | −$50.1M | −$63.6M | −$61.2M | −$98.0M |
| FCF margin | −160.5% | −329.2% | −261.3% | −235.6% | −1,371.4% |
| Dividends paid | $4.4M | $0.0M | — | — | — |
| Share count change | 251.0% | 152.3% | 19.6% | 0.4% | 129.0% |
| Debt and strength | |||||
| Cash and short-term investments | $149M | $173M | $109M | $47.2M | $146M |
| Shareholders' equity | $136M | $158M | $105M | $52.5M | $136M |
| Current ratio | 9.9x | 9.6x | 4.7x | 3.6x | 10.3x |
| Interest coverage | −167.2x | −272.5x | −311.4x | −438.0x | — |
| Returns and quality | |||||
| Return on equity | −177.6% | −41.1% | −49.9% | −80.8% | −21.8% |
| Return on tangible equity | −83.5% | −38.2% | −62.5% | −121.4% | −15.1% |
| Piotroski F-score | 2 | 2 | 2 | 2 | 3 |
| Altman Z'' | 4.6 | 6.3 | −1.4 | −14.7 | 3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.6M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Whitehawk Therapeutics, Inc. · WHWK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.33 a share, the company is worth $276M.
Source: SEC EDGAR XBRL filings (CIK 0001422142). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.